Sona Nanotech Inc. (SNANF)
OTCQB OTCQB Primary 
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced melanoma who had stopped responding to standard immunotherapy. The findings mark a major milestone for the Halifax-based nanotechnology company as it transitions from preclinical research to clinical development.
Sona Nanotech poised for clinical breakthrough after melanoma study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is stepping into clinical-stage biotech after reporting promising results from its first-in-human trial of Targeted Hyperthermia Therapy (THT) for advanced melanoma. The early feasibility study treated 10 patients whose melanoma had not responded to standard immunotherapies.
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) Inc announced that it has completed its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy. The company said by day 15, eight of 10 patients experienced a significant clinical response to treatment with a majority (six out of eight) showing no detectable residual melanoma in representative, biopsied tumors, and two patients showing no response.
Sona Nanotech advances first-in-human cancer therapy trial
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has completed treatment and follow-up assessments for the first cohort of patients in its early feasibility study of Targeted Hyperthermia Therapy (THT) for late-stage melanoma. The company, which is developing oncology-focused therapies based on its proprietary biocompatible gold nanorod technology, said it has received approval to begin treating the second patient cohort.
Sona Nanotech launches first human trial for groundbreaking cancer therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF), a clinical-stage biotech company specializing in nanotechnology-driven cancer treatments, has reached a significant milestone with the initiation of its first human clinical trial for a novel targeted hypothermia therapy (THT). The therapy aims to convert “cold” tumors — which typically evade immune detection — into “hot” tumors that respond to immunotherapy, potentially overcoming one of oncology's most stubborn challenges.
Sona Nanotech gains ethics nod for cancer trial - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's recent ethics committee approval for a pilot cancer study. This approval represents the next step in Sona Nanotech's clinical development pathway, building on its current early feasibility study focused on late-stage melanoma patients.
Sona Nanotech gets ethics board nod for pilot melanoma cancer trial in Canada
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said on Wednesday it has received approval from Nova Scotia's Health Research Ethics Board to proceed with a pilot human clinical trial of its gold nanorod-based cancer treatment in patients with late-stage melanoma. The multi-centre trial involving up to 40 patients will test Sona's Targeted Hyperthermia Therapy (THT), which uses biocompatible gold nanorods designed to destroy cancer cells with localized heat.
Sona Nanotech begins clinical trial for late-stage cancer – ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's first-in-human clinical trial using its THT therapy for late-stage melanoma patients. Regan explained that Sona has dosed the first patient in Santiago, Chile, marking a significant step from preclinical work into clinical testing.
Sona Nanotech doses first patient in cancer therapy feasibility study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has dosed the first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment. The study is evaluating the safety, tolerability, and preliminary efficacy of its THT therapy in patients with advanced melanoma who have not responded to standard immunotherapy treatments.
Sona Nanotech gets ethics committee nod to launch early-stage cancer therapy trial
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said it has received ethics committee approval to begin enrolling patients in an early feasibility study for its Targeted Hyperthermia Therapy (THT), a novel cancer treatment that uses the company's gold nanorod technology. The Halifax-based company said the trial will focus on patients with late-stage melanoma who have not responded to standard immunotherapy treatments.
Sona Nanotech signs Chile trial partner for targeted hyperthermia therapy trial - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's latest step in advancing its targeted hyperthermia therapy (THT) towards market approval. Speaking from a major biotech conference in Boston, Regan shared details on a newly signed clinical trial agreement in Chile.
Sona Nanotech engages clinic for first-in-human trial of THT cancer therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has entered into a clinical trial agreement for an early feasibility study of its Targeted Hyperthermia Therapy (THT) in advanced melanoma patients. The company is partnering with Bradford Hill Investigacion Clinica in Santiago, Chile, to conduct the study.
